Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€27.72

€27.72

-0.070%
-0.02
-0.070%
€36.28

€36.28

 
Latest predictions
-
06.02.21
buy
-
11.01.21
buy
€72.00
19.12.20
buy
€34.00
18.12.20
buy
€36.00
14.12.20
buy
-
12.12.20
buy
Your prediction

Pfizer Inc. Stock

There is nearly no change for the Pfizer Inc. stock today. Compared to yesterday it only changed by -€0.020.
With 28 Buy predictions and 2 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of €36.00 there is a positive potential of 29.894% for Pfizer Inc. compared to the current price of €27.72.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 7 users see the criterium "Brand" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.

Pros and Cons of Pfizer Inc. in the next few years

Pros
7
Known brand
7
Could be worthwhile Investment >10% per year
6
Market Leader or Top 3
Cons
4
Significant cyclical dependencies
3
Sustainability is little important

Performance of Pfizer Inc. vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Pfizer Inc. -0.070% -4.296% -7.765% -8.648% -8.314% -0.569% 7.671%
Eli Lilly Corp. -0.460% -1.948% -0.732% 32.077% 23.665% 163.244% 151.248%
Alexion Pharmaceutical Inc. -0.550% -2.577% -3.215% 39.169% -0.657% 35.676% -1.854%
Johnson & Johnson 1.060% -2.835% -0.595% -0.669% 5.945% 24.590% 40.178%

Comments

Buy Pfizer Inc.

Prediction Buy
Perf. (%) -10.01%
Target price 72.000
Change
Ends at 19.12.21

Buy with target price 72.0

Prediction Buy
Perf. (%) -13.49%
Target price 36.000
Change
Ends at 14.12.21

Buy with target price 36.0

Other discussions about Pfizer Inc. Stock

Trading Pfizer Inc.

Trading Pfizer Inc.

New thread Forum

News

U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)


Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, at the Cowen 41st Annual

Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myelomahttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma


Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an